 Gina Kruse
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking Cessation | 17 | 2025 | 447 | 6.220 |
Why?
| | Text Messaging | 5 | 2023 | 157 | 2.420 |
Why?
| | Early Detection of Cancer | 7 | 2025 | 420 | 2.140 |
Why?
| | Smoking | 8 | 2023 | 1639 | 1.660 |
Why?
| | Primary Health Care | 7 | 2023 | 1756 | 1.320 |
Why?
| | Tobacco Use | 3 | 2022 | 66 | 1.100 |
Why?
| | Smokers | 4 | 2020 | 148 | 1.060 |
Why?
| | Massachusetts | 8 | 2025 | 171 | 1.020 |
Why?
| | Colorectal Neoplasms | 4 | 2025 | 799 | 1.010 |
Why?
| | Tobacco Products | 3 | 2025 | 142 | 0.980 |
Why?
| | Tobacco Use Cessation | 2 | 2024 | 26 | 0.940 |
Why?
| | Tobacco Use Disorder | 3 | 2022 | 252 | 0.940 |
Why?
| | Electronic Nicotine Delivery Systems | 5 | 2025 | 109 | 0.920 |
Why?
| | Buprenorphine | 2 | 2025 | 168 | 0.840 |
Why?
| | Postal Service | 2 | 2020 | 34 | 0.840 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2024 | 255 | 0.820 |
Why?
| | Community Health Services | 2 | 2015 | 232 | 0.760 |
Why?
| | Laboratories | 1 | 2023 | 113 | 0.750 |
Why?
| | United States Indian Health Service | 2 | 2022 | 42 | 0.700 |
Why?
| | Patient Discharge | 3 | 2024 | 895 | 0.680 |
Why?
| | Mentoring | 1 | 2023 | 144 | 0.650 |
Why?
| | Electronic Health Records | 4 | 2016 | 1040 | 0.650 |
Why?
| | Alaska Natives | 1 | 2022 | 142 | 0.630 |
Why?
| | Papillomavirus Infections | 1 | 2023 | 331 | 0.600 |
Why?
| | Health Behavior | 3 | 2022 | 764 | 0.580 |
Why?
| | Community Health Centers | 5 | 2025 | 59 | 0.560 |
Why?
| | Pilot Projects | 6 | 2025 | 1703 | 0.560 |
Why?
| | Delivery of Health Care | 4 | 2023 | 948 | 0.560 |
Why?
| | Humans | 56 | 2025 | 137514 | 0.560 |
Why?
| | Rural Population | 3 | 2024 | 567 | 0.530 |
Why?
| | Meaningful Use | 1 | 2016 | 13 | 0.520 |
Why?
| | Indians, North American | 1 | 2022 | 625 | 0.490 |
Why?
| | Middle Aged | 22 | 2025 | 33355 | 0.490 |
Why?
| | Comorbidity | 2 | 2017 | 1618 | 0.470 |
Why?
| | HIV Infections | 7 | 2024 | 2830 | 0.470 |
Why?
| | Motivation | 2 | 2019 | 571 | 0.460 |
Why?
| | Smoke-Free Policy | 1 | 2014 | 15 | 0.450 |
Why?
| | Female | 34 | 2025 | 73162 | 0.450 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 49 | 0.440 |
Why?
| | Opiate Substitution Treatment | 3 | 2025 | 147 | 0.440 |
Why?
| | Smoking Prevention | 1 | 2015 | 188 | 0.440 |
Why?
| | Telemedicine | 2 | 2021 | 852 | 0.430 |
Why?
| | Male | 30 | 2025 | 67718 | 0.430 |
Why?
| | Adult | 26 | 2025 | 37821 | 0.420 |
Why?
| | Tobacco Smoking | 2 | 2024 | 28 | 0.410 |
Why?
| | Reimbursement, Incentive | 1 | 2013 | 37 | 0.410 |
Why?
| | Program Development | 1 | 2015 | 366 | 0.400 |
Why?
| | Counseling | 4 | 2024 | 393 | 0.400 |
Why?
| | Vaping | 2 | 2025 | 63 | 0.400 |
Why?
| | Lung Neoplasms | 1 | 2025 | 2494 | 0.380 |
Why?
| | Colonoscopy | 1 | 2014 | 247 | 0.380 |
Why?
| | Health Equity | 3 | 2024 | 99 | 0.370 |
Why?
| | Documentation | 1 | 2013 | 189 | 0.360 |
Why?
| | Telephone | 2 | 2023 | 170 | 0.360 |
Why?
| | Tobacco Smoke Pollution | 1 | 2014 | 284 | 0.360 |
Why?
| | Population Surveillance | 1 | 2014 | 474 | 0.350 |
Why?
| | Neoplasms | 2 | 2023 | 2666 | 0.350 |
Why?
| | Cross-Sectional Studies | 9 | 2025 | 5427 | 0.320 |
Why?
| | Anti-HIV Agents | 2 | 2014 | 775 | 0.320 |
Why?
| | Hospitalization | 2 | 2021 | 2197 | 0.310 |
Why?
| | Referral and Consultation | 2 | 2012 | 780 | 0.290 |
Why?
| | Opioid-Related Disorders | 2 | 2025 | 510 | 0.260 |
Why?
| | Aged | 12 | 2025 | 23798 | 0.260 |
Why?
| | Students | 2 | 2022 | 625 | 0.260 |
Why?
| | United States | 8 | 2025 | 14696 | 0.260 |
Why?
| | Boston | 3 | 2024 | 92 | 0.250 |
Why?
| | Flavoring Agents | 1 | 2025 | 13 | 0.240 |
Why?
| | South Africa | 2 | 2024 | 219 | 0.240 |
Why?
| | Feasibility Studies | 2 | 2022 | 950 | 0.230 |
Why?
| | Appointments and Schedules | 2 | 2002 | 89 | 0.230 |
Why?
| | Occult Blood | 1 | 2024 | 34 | 0.220 |
Why?
| | Faculty | 2 | 2022 | 143 | 0.220 |
Why?
| | Pandemics | 3 | 2021 | 1619 | 0.220 |
Why?
| | India | 2 | 2024 | 193 | 0.220 |
Why?
| | Patient Compliance | 2 | 2012 | 586 | 0.210 |
Why?
| | Outpatients | 2 | 2024 | 393 | 0.210 |
Why?
| | Mental Disorders | 2 | 2002 | 1083 | 0.210 |
Why?
| | Social Determinants of Health | 2 | 2024 | 251 | 0.210 |
Why?
| | Narcotic Antagonists | 1 | 2025 | 178 | 0.200 |
Why?
| | Vaginal Smears | 1 | 2023 | 56 | 0.200 |
Why?
| | Safety-net Providers | 1 | 2024 | 117 | 0.190 |
Why?
| | Cooperative Behavior | 1 | 2025 | 447 | 0.190 |
Why?
| | Papillomaviridae | 1 | 2023 | 126 | 0.190 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2002 | 83 | 0.190 |
Why?
| | Interrupted Time Series Analysis | 1 | 2022 | 66 | 0.190 |
Why?
| | Medically Underserved Area | 1 | 2022 | 87 | 0.190 |
Why?
| | Treatment Refusal | 1 | 2002 | 89 | 0.190 |
Why?
| | Student Run Clinic | 1 | 2021 | 3 | 0.180 |
Why?
| | Mass Screening | 3 | 2025 | 1264 | 0.180 |
Why?
| | Tuberculosis | 1 | 2024 | 281 | 0.180 |
Why?
| | Behavior Therapy | 2 | 2022 | 262 | 0.180 |
Why?
| | Pain Management | 1 | 2005 | 363 | 0.180 |
Why?
| | Patient Participation | 1 | 2005 | 423 | 0.180 |
Why?
| | Medication Adherence | 1 | 2025 | 471 | 0.170 |
Why?
| | Education, Medical, Undergraduate | 1 | 2023 | 186 | 0.170 |
Why?
| | Ambulatory Care | 1 | 2024 | 539 | 0.160 |
Why?
| | Physician-Patient Relations | 1 | 2005 | 552 | 0.160 |
Why?
| | Developing Countries | 2 | 2015 | 305 | 0.160 |
Why?
| | Prevalence | 4 | 2025 | 2719 | 0.160 |
Why?
| | Interviews as Topic | 3 | 2019 | 767 | 0.160 |
Why?
| | Longitudinal Studies | 2 | 2020 | 2857 | 0.160 |
Why?
| | Community Networks | 1 | 2020 | 60 | 0.160 |
Why?
| | Education, Medical | 1 | 2023 | 260 | 0.160 |
Why?
| | Crisis Intervention | 1 | 2019 | 33 | 0.160 |
Why?
| | Analgesics, Opioid | 2 | 2024 | 1002 | 0.150 |
Why?
| | Pain | 1 | 2005 | 836 | 0.150 |
Why?
| | Preventive Health Services | 1 | 2020 | 149 | 0.150 |
Why?
| | Nevirapine | 2 | 2008 | 17 | 0.140 |
Why?
| | Cohort Studies | 5 | 2025 | 5730 | 0.140 |
Why?
| | Students, Medical | 1 | 2023 | 341 | 0.140 |
Why?
| | Young Adult | 6 | 2025 | 13243 | 0.140 |
Why?
| | Organophosphonates | 2 | 2008 | 92 | 0.140 |
Why?
| | Decision Making | 1 | 2005 | 906 | 0.140 |
Why?
| | Surveys and Questionnaires | 4 | 2019 | 5772 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1465 | 0.130 |
Why?
| | Communication | 1 | 2023 | 874 | 0.130 |
Why?
| | Deoxycytidine | 2 | 2008 | 176 | 0.130 |
Why?
| | Adolescent | 8 | 2025 | 21555 | 0.130 |
Why?
| | Caregivers | 1 | 2024 | 872 | 0.130 |
Why?
| | Liver Transplantation | 1 | 2024 | 872 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2021 | 368 | 0.130 |
Why?
| | Texas | 4 | 2005 | 246 | 0.130 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2008 | 182 | 0.120 |
Why?
| | Diabetes Mellitus | 1 | 2024 | 1035 | 0.120 |
Why?
| | Adenine | 2 | 2008 | 268 | 0.120 |
Why?
| | Diffusion of Innovation | 1 | 2016 | 98 | 0.120 |
Why?
| | Focus Groups | 2 | 2022 | 512 | 0.120 |
Why?
| | Hypertension | 1 | 2024 | 1293 | 0.120 |
Why?
| | Allied Health Personnel | 1 | 2015 | 46 | 0.120 |
Why?
| | Qualitative Research | 2 | 2019 | 1361 | 0.120 |
Why?
| | Community Health Workers | 1 | 2015 | 61 | 0.110 |
Why?
| | Automobiles | 1 | 2014 | 19 | 0.110 |
Why?
| | Health Surveys | 1 | 2017 | 520 | 0.110 |
Why?
| | Uganda | 1 | 2014 | 72 | 0.110 |
Why?
| | Logistic Models | 3 | 2017 | 2064 | 0.110 |
Why?
| | Colonic Polyps | 1 | 2014 | 88 | 0.100 |
Why?
| | Odds Ratio | 3 | 2008 | 1063 | 0.100 |
Why?
| | Program Evaluation | 2 | 2020 | 892 | 0.100 |
Why?
| | Residence Characteristics | 2 | 2014 | 354 | 0.100 |
Why?
| | Patient Admission | 1 | 2014 | 191 | 0.100 |
Why?
| | Managed Care Programs | 1 | 2013 | 129 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1116 | 0.100 |
Why?
| | Health Services Accessibility | 4 | 2024 | 976 | 0.100 |
Why?
| | Hospitals, Psychiatric | 2 | 2002 | 26 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2021 | 1115 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 3 | 2022 | 809 | 0.100 |
Why?
| | Social Class | 1 | 2014 | 277 | 0.090 |
Why?
| | Prospective Studies | 3 | 2025 | 7598 | 0.090 |
Why?
| | HIV-1 | 2 | 2008 | 863 | 0.090 |
Why?
| | Nurses | 1 | 2014 | 174 | 0.090 |
Why?
| | Feedback | 1 | 2012 | 174 | 0.090 |
Why?
| | Health Plan Implementation | 1 | 2012 | 140 | 0.090 |
Why?
| | Quality Assurance, Health Care | 1 | 2013 | 324 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2024 | 5139 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 2054 | 0.090 |
Why?
| | Hospitals | 1 | 2014 | 678 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2521 | 0.070 |
Why?
| | Retrospective Studies | 4 | 2022 | 15628 | 0.070 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2007 | 84 | 0.070 |
Why?
| | Patient Care Team | 1 | 2012 | 629 | 0.070 |
Why?
| | Chronic Disease | 1 | 2013 | 1790 | 0.070 |
Why?
| | Drug Resistance, Viral | 1 | 2007 | 115 | 0.070 |
Why?
| | Renal Insufficiency | 1 | 2008 | 157 | 0.060 |
Why?
| | Anti-Retroviral Agents | 1 | 2008 | 235 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2024 | 7593 | 0.060 |
Why?
| | Insurance, Health | 2 | 2005 | 282 | 0.060 |
Why?
| | Behavioral Risk Factor Surveillance System | 1 | 2025 | 52 | 0.060 |
Why?
| | Risk Factors | 2 | 2014 | 10356 | 0.060 |
Why?
| | Regression Analysis | 2 | 2005 | 1029 | 0.060 |
Why?
| | Insurance Coverage | 2 | 2022 | 228 | 0.050 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2008 | 389 | 0.050 |
Why?
| | Vaccination | 2 | 2022 | 1398 | 0.050 |
Why?
| | Quality Improvement | 1 | 2012 | 1161 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2022 | 1060 | 0.050 |
Why?
| | Housing | 1 | 2024 | 146 | 0.050 |
Why?
| | Social Networking | 1 | 2023 | 34 | 0.050 |
Why?
| | Rural Health Services | 1 | 2004 | 128 | 0.050 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2022 | 66 | 0.050 |
Why?
| | Mobile Health Units | 1 | 2022 | 21 | 0.050 |
Why?
| | Health Status | 2 | 2005 | 784 | 0.050 |
Why?
| | Health Services for the Aged | 1 | 2003 | 73 | 0.050 |
Why?
| | Midwestern United States | 1 | 2002 | 45 | 0.050 |
Why?
| | Hospitals, University | 1 | 2002 | 181 | 0.050 |
Why?
| | Varenicline | 1 | 2022 | 25 | 0.050 |
Why?
| | Bupropion | 1 | 2022 | 45 | 0.050 |
Why?
| | Quality of Life | 2 | 2022 | 2870 | 0.050 |
Why?
| | Stakeholder Participation | 1 | 2022 | 77 | 0.050 |
Why?
| | Schools, Medical | 1 | 2023 | 146 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2007 | 740 | 0.050 |
Why?
| | Continuity of Patient Care | 1 | 2004 | 279 | 0.050 |
Why?
| | Meals | 1 | 2022 | 122 | 0.040 |
Why?
| | England | 1 | 2021 | 99 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2022 | 163 | 0.040 |
Why?
| | HIV | 1 | 2022 | 233 | 0.040 |
Why?
| | Data Collection | 1 | 2024 | 674 | 0.040 |
Why?
| | Minority Groups | 1 | 2022 | 269 | 0.040 |
Why?
| | Poverty | 1 | 2024 | 520 | 0.040 |
Why?
| | Urban Population | 1 | 2003 | 475 | 0.040 |
Why?
| | Triage | 1 | 2021 | 221 | 0.040 |
Why?
| | Medicaid | 1 | 2003 | 436 | 0.040 |
Why?
| | Learning | 1 | 2023 | 430 | 0.040 |
Why?
| | Zambia | 2 | 2008 | 57 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2012 | 10821 | 0.030 |
Why?
| | Medicare | 1 | 2003 | 747 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1580 | 0.030 |
Why?
| | Emtricitabine | 2 | 2008 | 174 | 0.030 |
Why?
| | Tenofovir | 2 | 2008 | 240 | 0.030 |
Why?
| | Curriculum | 1 | 2023 | 980 | 0.030 |
Why?
| | Child | 2 | 2024 | 22037 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3546 | 0.020 |
Why?
| | Socioeconomic Factors | 2 | 2004 | 1286 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 533 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2008 | 272 | 0.020 |
Why?
| | Creatinine | 1 | 2008 | 501 | 0.020 |
Why?
| | Risk | 1 | 2008 | 905 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2008 | 1263 | 0.010 |
Why?
| | Pregnancy | 2 | 2008 | 6745 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2008 | 746 | 0.010 |
Why?
| | Health Status Indicators | 1 | 2004 | 171 | 0.010 |
Why?
| | Office Visits | 1 | 2003 | 91 | 0.010 |
Why?
| | Health Care Surveys | 1 | 2003 | 567 | 0.010 |
Why?
| | Disease Progression | 1 | 2008 | 2755 | 0.010 |
Why?
| | Biomarkers | 1 | 2008 | 4172 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2007 | 6059 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2004 | 1332 | 0.010 |
Why?
|
|
Kruse's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|